Protective effects of orally applied fullerenol nanoparticles in rats after a single dose of doxorubicin;Zaštitni efekat oralno unetih fulerenolskih nanočestica na pacove nakon jednokratratne primene doksorubicina

Hemijska Industrija

Volumn 65, Issue 3, 2011, Pages 329-337

  Ičević, Ivana D J ^a   Vukmirović, Saša N ^b   Srdenović, Branislava U ^b   Sudji, Jan J ^c   Djordjevic, Aleksandar N ^a   Injac, Rade M ^d   Vasović, Velibor M ^b  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c The Institute for the Health Protection of Workers Novi Sad   (Serbia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Doxorubicine; Fullerenol; In vivo; Nano particles; Oral application

Indexed keywords

EID: 79960313737     PISSN: 0367598X     EISSN: 0350249X     Source Type: Journal    
DOI: 10.2298/HEMIND101231006I     Document Type: Article

References (26)

1. J.L. Quiles, J.R. Huertas, M. Battino, J. mataix, M.C. Ramirez-Tortosa, Antioxidant nutrients and adriamycin toxicity, Toxicology 180 (2002) 79-95.
2. V. Box, The intercalation of DNA double helices with doxorubicin and nagalomycin, J. Mol. Graph Mod 26 (2007) 14-19.
3. N. Ashley, J. Poulton, Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs, Biochem. Biophys. Res. Co. 378 (2009) 450-455.
4. Y. Kalender, M. Yel, S. Kalender, Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effect of vitamin E and catehin, Toxicology 209 (2005) 39-45.
5. S.V. Kalivendi, E.A. Konorev, S. Cunningham, S.K. Vanamal, E.H. Kaji, J. Joseph, B. Kayanaraman, Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium, Biochem. J. 389 (2005) 527-539.
6. G. Takemura, H. Fujiwara, Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis. 49 (2007) 330-352.
7. P.K. Singal, N. Iliskovic, Doxorubicin induced cardiomyopathy, N. Engl. J. Med. 339 (1998) 900-905.
8. R.T.V. Santos, Jr. M.I. Batirsta, E.C. Caperuto, L.F.B.P. Costa Rosa, Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after doxorubicin treatment in rats, Clin. Exp. Pharmacol. Physiol. 34 (2007) 1294-1299.
9. E. Winer, M. Morrow, C.K. Osborne, J.R. Harris, in: Cancer: Principles and practice ofoncology, V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 1651-1717.
10. K. Riehemann, S.W. Schneider, T.A. Luger, B. Godin, M. Ferrari, H. Fuchs, Nanomedicine-challenge and perspectives, Angew. Chem. Int. Ed. Engl. 48 (2009) 872-897.
11. S.D. Caruthers, S.A. Wickline, G.M. Lanza, Nanotechnological applications in medicine, Curr. Opin. Biotech. 18 (2007) 26-30.
12. K.K. Jain, Role of nanobiotechnology in the development of personalized medicine, Nanomed. 4 (2009) 249-252.
13. J.A. Brant, J. Labille, J.Y. Bottero, C.O. Robichaud, M. Wiesner, Fullerol cluster formation in aqueous solu-tions: Implications for environmental release, J. Colloid Interface Sci. 314 (2007):281-288.
14. A. Djordjevic, G. Bogdanovic, Archive of Oncology 16 (2008) 42-45.
15. 24 effects on antioxidative enzymes activity in irradiated human erythroleukemia cell line, J. Radiat. Res. 49 (2008) 321-327.
16. 24 and amifostine in irradiated rats, Coll. Surf. B. 58 (2007) 39-43.
17. 24 on the frequency of micronuclei and chromosome aberrations in CHO-K1 cells, Mutat. Res.-Gen. Tox. En. 680 (2009) 25-30.
18. 24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer, Biomaterials 30 (2009) 1184-1196.
19. J.J. Yin, F. Lao, P.P. Fu, W.G. Wamer, Y. Zhao, P.C. Wang, Y. Qin, B. Sun, G. Xing, J. Dong, X.J. Liang, C. Chen, The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials, Biomaterials 30 (2009) 611-621.
20. X. Jing-Ying, S. Yuan-Yuan, C. Jin-Sheng, L. Shu-Xia, L. Ruili, L. Wen-Xin, X. Guo-Tong, L. Qing-Nuan, Protective effects of fullerenol on carbon tetrachloride-induced acute hepatotoxicity and nephrotoxicity in rats, Carbon 48 (2009) 1388-1396.
21. 24, Fullerene. Sci. Technol. 6 (1998) 689-694.
22. 24 in doxorubicin induced hepatotoxicity in rats with mammary carcinomas, Biomaterials 24-25 (2008) 3451-3460.
23. 24 via suppression of oxidative stress, Pharmacol. Rep. 60 (2008) 742-749.
24. 24 on doxorubicin-induced hepatotoxicity in rats: pathohistological study. Toxicol. Lett. 172 (2007) 146.
25. 24 on a single dose doxorubicin induced cardiotoxicity in rats with malignant neoplasm, Technol. Cancer. Res. Treat. 7 (2008) 15-26.
26. 24. Toxicol. Mech. Method. 19 (2009) 24-28.